SPEEDX
30.6.2021 10:21:09 CEST | Business Wire | Press release
SpeeDx Pty, Ltd. and MolGen announced the signing of an agreement to collaborate on supply and distribution of clinical diagnostics products and instrumentation across Europe and Asia Pacific. The partnership links specimen handling, nucleic acid extraction, assay set-up, amplification, and results reporting in a seamless integration of the companies technologies.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210630005407/en/
“This partnership capitalises on the existing infrastructure of our two companies and the strength of our synergies,” said Colin Denver, SpeeDx CEO. “Our commitment to providing products and services that answer unmet clinical needs also extends to the pathology laboratories that are running our tests – in partnership with MolGen, we can address much of their workflow concerns and offer a more complete testing solution.”
Throughout the past year of COVID-19, in response to the increased demand for molecular testing workflow solutions, MolGen has developed a comprehensive offering including the PurePrep nucleic acid extraction portfolio, liquid handling instrumentation and other purpose-built automation to facilitate high-volume testing of SARS-CoV-2. SpeeDx complete the partnership with an initial offer of their CE-IVD SARS-CoV-2 test based on their proprietary Plex PCR® technology, allowing pathology laboratories a single point of contact to fulfil their testing needs.
“For MolGen, the collaboration with SpeeDx is a perfect example of combining the best of both worlds. Our DNA and RNA extraction solutions and automated workflow perfectly pair with SpeeDx diagnostic assay technology” said Maarten de Groot, MolGen CEO. “During the COVID pandemic adding the CE-IVD SARS-CoV-2 assay to our diagnostics portfolio is great opportunity to start our collaboration. And this is only the beginning of jointly building an innovative product portfolio”.
About SpeeDx
Founded in 2009, SpeeDx is an Australian-based private company with subsidiary offices in Austin, Texas and London, UK, with distributors across Europe. SpeeDx specializes in molecular diagnostic solutions that go beyond simple detection to offer comprehensive information for improved patient management. Innovative real-time polymerase chain reaction (qPCR) technology has driven market-leading multiplex detection and priming strategies. Product portfolios focus on multiplex diagnostics for sexually transmitted infection (STI), antibiotic resistance markers, and respiratory disease. For more information on SpeeDx please see: https://plexpcr.com
About MolGen
MolGen is global total solution provider of innovative extraction DNA / RNA technology, system, products and kits for human and animal diagnostics, the agriculture and biotech industries which reduce hands-on time and increase productivity while maintaining high yields and reproducibility.
From sample to result, MolGen is challenging the status quo in molecular diagnostics by offering platform stand-alone systems and consumables. Highly customizable, MolGen’s portfolio offers the perfect workflow for our customers’ specific needs, being high-quality, adaptable and safe.
Due to travel restrictions Maarten de Groot, MolGen CEO and Colin Denver, SpeeDx CEO joined a virtual session to officially announce the collaboration that will combine Molgen liquid handling and purpose-built automation with SpeeDx COVID-19 diagnostic solutions - extending a full workflow offering to pathology laboratories.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210630005407/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Approval Granted for Commercial Manufacturing at Rezon Bio's Warsaw-Duchnice Facility18.2.2026 14:01:00 CET | Press release
Rezon Bio announces that its Warsaw-Duchnice facility has received approval from the U.S. Food and Drug Administration (FDA) for the commercial manufacturing of a biosimilar. This milestone represents an important step in the continued development of Rezon Bio’s global manufacturing network and reflects the company’s focus on building robust, compliant, and reliable capabilities to support biologic therapies for patients worldwide. The FDA approval of the Warsaw-Duchnice facility follows a comprehensive review process and reflects the maturity of the site’s quality systems, technical capabilities, and operational readiness for commercial supply to the US market. This approval is coming subsequent to previous EMA GMP certification and approval for commercial supply to European markets. Such approval further strengthens Rezon Bio’s ability to support clients in needs to supply EU and US territories and enhances its position as a reliable partner within the Contract Development and Manufa
Vasion® Achieves FedRAMP® High Authorization, Meeting Federal Cloud Security Gold Standard18.2.2026 14:00:00 CET | Press release
FedRAMP Authorization validates Vasion’s secure, cloud-native, intelligent physical and digital print automation platform as trusted to modernize federal agency operations. Vasion, a leader in serverless printing and Intelligent Print Automation, today announced it has achieved FedRAMP® High Authorization to Operate (ATO) through the Federal Risk and Authorization Management Program. This authorization represents the most rigorous security compliance standard for the government sector. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260218295773/en/ At V3, Vasion Co-Founder and CEO Ryan Wedig unveiled the Intelligent Print Automation platform and challenged every Vasioneer to embrace a Mission of Aspirational Performance that demands collaboration, creativity, and courage. With Vasion's recent FedRAMP High Authorization, the company is making digital transformation attainable for everyone, including federal agencies with the
TreviPay Announces AI-Powered Growth Center to Help Enterprises Predict Buyer Behavior and Drive B2B Sales18.2.2026 14:00:00 CET | Press release
The new product offering uses machine learning to support targeted buyer engagement and rebate incentives TreviPay, a fully managed B2B payments platform, today announced the availability of the Growth Center, a set of capabilities within the TreviPay Client Portal to help identify buyer growth opportunities more strategically and build stronger, longer-lasting supplier relationships. With its advanced features, the new Growth Center enables businesses to explore buyer needs, spot trends and optimize key steps in the order-to-cash (O2C) process. Integrated into TreviPay’s global payments network, the customizable add-ons will help businesses use their O2C programs to deepen buyer relationships and drive lasting engagement. For many suppliers, growth is not only about bringing in new buyers. It also means keeping existing buyers engaged, spotting early signs of dormancy and giving sales, operations and finance teams a practical way to act without adding friction. By combining transactio
ICR Appoints Sukanti Ghosh as Partner, International Strategy & Markets18.2.2026 13:00:00 CET | Press release
Global Strategic Communications leader to drive ICR's expansion across Europe, Middle East, South Asia, and Africa ICR, a leading strategic communications and advisory firm, today announced the appointment of Sukanti Ghosh as Partner, International Strategy & Markets, effective February 2, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260218511412/en/ Sukanti Ghosh headshot Based in London, Mr. Ghosh brings more than three decades of experience in global corporate affairs, financial communications, strategy, and issues management to ICR as the firm continues to grow its international footprint in Europe and across the Middle East, South Asia, and Africa. Mr. Ghosh joins ICR from the Vedanta Group, a $20bn diversified mining, energy and technology conglomerates, where he served as President of Global Policy & Communications and led financial communications for the group, globally. During his tenure, he also played a ce
Macrobond Recognized in G2’s 2026 Best Software Awards for Financial Services and New Software18.2.2026 13:00:00 CET | Press release
Macrobond, the global platform for macroeconomic and financial data, today announced it has been named to G2’s 2026 Best Software Awards, earning recognition in the Best Financial Services Software Products and Best New Software Products categories. As the world’s largest and most trusted software marketplace, G2 reaches more than 100 million buyers annually. Its annual Best Software Awards rank the world’s leading software companies and products based on authentic, timely reviews from real users. “As buyers increasingly shift to AI driven research to discover software solutions, being recommended in the answer moment must be earned with credible proof,” said Godard Abel, co founder and CEO at G2. “Our Best Software Awards are grounded in trusted data from authentic customer reviews. They not only give buyers an objective, reliable guide to the products that help teams do their best work, but they are also the proof AI search platforms rely on when sourcing answers. Congratulations to
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom